CPTx, a biotechnology company developing in vivo genetic medicines built with programmable single-stranded DNA (ssDNA), announces that the QUIET-CAR collaborative project with NanoCell Therapeutics has received a Eurostars Grant from the European Union through the Horizon Europe programme and Eureka Network.
The focus of the QUIET-CAR project is the development of targeted lipid nanoparticles carrying novel immune-silent ssDNA for in vivo CAR T therapy.
"CPTx is committed to bringing in vivo CAR T therapies to patients through our proprietary pipeline development programmes and now also through the QUIET-CAR project with NanoCell,” said Hendrik Dietz, CEO of CPTx.
“The QUIET-CAR project represents another innovative approach to CAR T, and we look forward to advancing it together."
"Being selected from so many high-quality submissions underscores the promise of the project and the strength of our technology."
Eurostars, part of the European Partnership on Innovative SMEs and supported by Horizon Europe, is a funding initiative to accelerate transnational innovation.
With participation from 37 countries, the programme selects only the most promising technological breakthroughs, evaluated by independent experts.
The selection of the CPTx/NanoCell project from more than 120 proposals reflects QUIET-CAR’s strong scientific and clinical potential across oncology and autoimmune diseases.
NanoCell Therapeutics is a privately held biotechnology company pioneering transformative in vivo cell engineering through its non-viral, DNA-based gene therapy platform, primarily targeting oncology and autoimmune diseases.
Read more about CPtx's research here.
